AbbVie Inc (ABBV)vsQuoin Pharmaceuticals Ltd DRC (QNRX)
ABBV
AbbVie Inc
$206.60
-2.23%
HEALTHCARE · Cap: $360.63B
QNRX
Quoin Pharmaceuticals Ltd DRC
$6.21
-4.17%
HEALTHCARE · Cap: $9.83M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
QNRX
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$206.60
$43.01 premium
Intrinsic value data unavailable for QNRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : QNRX
The strongest argument for QNRX centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : QNRX
The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
QNRX carries more volatility with a beta of 1.82 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Quoin Pharmaceuticals Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology company dedicated to developing innovative therapeutics targeting rare diseases and unmet medical needs. Leveraging advanced drug delivery technologies, Quoin aims to improve the efficacy and safety of existing compounds, thereby strengthening its foothold in the specialty pharmaceuticals landscape. The company's promising pipeline features therapies addressing critical health conditions, offering potential for significant clinical advancements and commercial opportunities. Committed to delivering value for patients and investors alike, Quoin actively pursues strategic collaborations and pioneering research initiatives.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?